SEC Tracker
Get the app

Outlook Therapeutics OTLK

Outlook Therapeutics (OTLK) filed an 8-K reporting the resignation of its Chief Executive Officer, effective immediately. This unexpected leadership change introduces uncertainty around the company's strategic direction and ability to execute on its pipeline of ophthalmic drug candidates, which could impact investor confidence and the stock price.

Form
8-K
Filed
Importance
Major

Open in the appGet the appView on EDGAR

Get an email when Outlook Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. OnKure Therapeutics OKUR public float $28M, Jun 30, 2025
  2. Palatin Technologies PTN public float $26M, Dec 31, 2025
  3. Scynexis SCYX public float $26M, Jun 30, 2025
  4. Champions Oncology CSBR public float $29M, Oct 31, 2025
  5. Rockwell Medical RMTI public float $29M, Jun 30, 2025